JOSHUA W KIM
- Type
- Physician · Allopathic & Osteopathic Physicians / Ophthalmology
- Where
- VENICE, FL
- NPI
- 1740391952
- Received
- $210,490 in 433 records, 2019 to 2025 ($199,923 general, $10,566 research)
- As principal investigator
- $477,317 of research payments to others in 254 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 40 | $6,947 |
| 2024 | General payment | 46 | $27,360 |
| 2023 | General payment | 61 | $23,769 |
| 2022 | General payment | 44 | $29,456 |
| 2021 | General payment | 66 | $32,333 |
| 2020 | General payment | 38 | $16,994 |
| 2019 | General payment | 134 | $63,061 |
| 2019 | Research payment | 4 | $10,566 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| ABBVIE INC. | 62 | $51,437 | 2022–2025 |
| Aerie Pharmaceuticals, Inc. | 71 | $50,901 | 2019–2021 |
| Allergan, Inc. | 95 | $30,218 | 2019–2022 |
| Glaukos Corporation | 83 | $25,727 | 2019–2025 |
| Bausch & Lomb, a division of Bausch Health US, LLC | 25 | $19,948 | 2019–2021 |
| Alcon Vision LLC | 28 | $16,047 | 2022–2025 |
| Bausch Health US, LLC | 2 | $10,250 | 2019 |
| Bausch & Lomb Americas Inc. | 12 | $3,248 | 2022–2025 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $708 | 2019–2025 |
| Ivantis, Inc | 6 | $466 | 2019–2021 |
| Sight Sciences, Inc. | 14 | $337 | 2023–2025 |
| RxSight Inc | 3 | $269 | 2022–2025 |
| Tarsus Pharmaceuticals, Inc. | 2 | $243 | 2025 |
| NEW WORLD MEDICAL,INC. | 4 | $216 | 2023–2025 |
| Nova Eye, Inc. | 1 | $127 | 2024 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 2 | $114 | 2021–2022 |
| Apellis Pharmaceuticals, Inc. | 1 | $106 | 2023 |
| Rayner Intraocular Lenses Limited | 3 | $49 | 2022–2024 |
| Omeros Corporation | 2 | $38 | 2021 |
| Halozyme Inc | 1 | $16 | 2019 |
| LENSAR, Inc. | 1 | $16 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 43 | $115,833 |
| Consulting Fee | 14 | $23,527 |
| Travel and Lodging | 64 | $15,903 |
| Acquisitions | 1 | $13,903 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 6 | $13,025 |
| Food and Beverage | 295 | $12,756 |
| Research payment | 4 | $10,566 |
| Honoraria | 4 | $4,500 |
| Compensation for serving as faculty or as a speaker for a medical education program | 1 | $375 |
| Gift | 1 | $99 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | NEW WORLD MEDICAL,INC. | $155 | Food and Beverage | In-kind items and services | Kahook Dual Blade Device, Ophthalmology | 2025 | |
| 2025-12-13 | Johnson & Johnson Surgical Vision, Inc. | $48 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-04 | Glaukos Corporation | $38 | Food and Beverage | Cash or cash equivalent | iDoseTR Drug, Ophthalmology | 2025 | |
| 2025-12-03 | ABBVIE INC. | $2,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2025 | |
| 2025-11-19 | Bausch & Lomb Americas Inc. | $19 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-11-19 | Bausch & Lomb Americas Inc. | $2 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-11-06 | Tarsus Pharmaceuticals, Inc. | $121 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-11-05 | Bausch & Lomb Americas Inc. | $2,550 | Consulting Fee | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-29 | Glaukos Corporation | $450 | Consulting Fee | Cash or cash equivalent | Travoprost Intraocular Implant - iDose Drug, Ophthalmology | 2025 | |
| 2025-10-27 | Glaukos Corporation | $28 | Food and Beverage | Cash or cash equivalent | iDoseTR Drug, Ophthalmology | 2025 | |
| 2025-10-23 | Alcon Vision LLC | $120 | Food and Beverage | In-kind items and services | Clareon Device, Ophthalmology | 2025 | |
| 2025-10-17 | Bausch & Lomb Americas Inc. | $89 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-10-16 | Sight Sciences, Inc. | $22 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2025 | |
| 2025-10-16 | Sight Sciences, Inc. | $18 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2025 | |
| 2025-09-23 | Alcon Vision LLC | $19 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2025 | |
| 2025-09-10 | ABBVIE INC. | $145 | Food and Beverage | In-kind items and services | NATRELLE SALINE-FILLED BREAST IMPLANTS Device, PLASTIC SURGERY | 2025 | |
| 2025-08-18 | NEW WORLD MEDICAL,INC. | $18 | Food and Beverage | In-kind items and services | Kahook Dual Blade Device, Ophthalmology | 2025 | |
| 2025-06-19 | RxSight Inc | $115 | Food and Beverage | In-kind items and services | RXSIGHT CONTACT LENS Device, OPHTHALMOLOGY | 2025 | |
| 2025-06-18 | Bausch & Lomb Americas Inc. | $36 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2025 | |
| 2025-06-05 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2025-06-03 | Glaukos Corporation | $26 | Food and Beverage | Cash or cash equivalent | iDoseTR Drug, Ophthalmology | 2025 | |
| 2025-06-02 | Alcon Vision LLC | $25 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2025 | |
| 2025-05-23 | Johnson & Johnson Surgical Vision, Inc. | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-12 | Sight Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2025 | |
| 2025-05-05 | Alcon Vision LLC | $16 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2025 | |
| 2025-04-23 | Glaukos Corporation | $24 | Food and Beverage | Cash or cash equivalent | iDoseTR Drug, Ophthalmology | 2025 | |
| 2025-04-14 | NEW WORLD MEDICAL,INC. | $20 | Food and Beverage | In-kind items and services | Kahook Dual Blade Device, Ophthalmology | 2025 | |
| 2025-04-03 | Bausch & Lomb Americas Inc. | $43 | Food and Beverage | In-kind items and services | XIPERE Drug, Ophthalmology | 2025 | |
| 2025-03-19 | Glaukos Corporation | $135 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-03-17 | Sight Sciences, Inc. | $23 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2025 | |
| 2025-03-10 | Sight Sciences, Inc. | $19 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2025 | |
| 2025-03-07 | Glaukos Corporation | $22 | Food and Beverage | Cash or cash equivalent | Radius XR Device, Ophthalmology | 2025 | |
| 2025-03-06 | ABBVIE INC. | $99 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2025 | |
| 2025-02-27 | Glaukos Corporation | $31 | Food and Beverage | Cash or cash equivalent | iDoseTR Drug, Ophthalmology | 2025 | |
| 2025-02-25 | Alcon Vision LLC | $17 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2025 | |
| 2025-02-19 | Glaukos Corporation | $25 | Food and Beverage | Cash or cash equivalent | iDoseTR Drug, Ophthalmology | 2025 | |
| 2025-02-19 | Glaukos Corporation | $6 | Food and Beverage | Cash or cash equivalent | iDoseTR Drug, Ophthalmology | 2025 | |
| 2025-01-23 | Tarsus Pharmaceuticals, Inc. | $121 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2025 | |
| 2025-01-17 | Glaukos Corporation | $28 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-01-13 | Glaukos Corporation | $21 | Food and Beverage | Cash or cash equivalent | iDoseTR Drug, Ophthalmology | 2025 | |
| 2024-12-03 | ABBVIE INC. | $4,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-12-02 | Sight Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2024 | |
| 2024-11-25 | ABBVIE INC. | $2,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-11-14 | ABBVIE INC. | $1,151 | Travel and Lodging | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-11-14 | ABBVIE INC. | $109 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-10-30 | Glaukos Corporation | $6,400 | Consulting Fee | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-10-30 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | 2024 | |
| 2024-10-22 | Glaukos Corporation | $20 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-10-02 | Sight Sciences, Inc. | $118 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2024 | |
| 2024-09-18 | Glaukos Corporation | $2,058 | Travel and Lodging | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-09-18 | Glaukos Corporation | $264 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-09-18 | Sight Sciences, Inc. | $14 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2024 | |
| 2024-09-17 | Bausch & Lomb Americas Inc. | $22 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2024 | |
| 2024-09-09 | Sight Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2024 | |
| 2024-08-29 | Glaukos Corporation | $26 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-08-19 | Glaukos Corporation | $27 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-07-12 | Glaukos Corporation | $20 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-07-09 | Nova Eye, Inc. | $127 | Food and Beverage (2 payments) | In-kind items and services | 2024 | ||
| 2024-07-08 | Sight Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2024 | |
| 2024-06-17 | Glaukos Corporation | $26 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-06-14 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | DURYSTA Drug, EYE CARE | 2024 | |
| 2024-06-03 | ABBVIE INC. | $4,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-05-21 | ABBVIE INC. | $675 | Consulting Fee | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-05-14 | Bausch & Lomb Americas Inc. | $39 | Food and Beverage | In-kind items and services | XIIDRA Drug, Ophthalmology | 2024 | |
| 2024-05-13 | Glaukos Corporation | $20 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-05-09 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-05-09 | ABBVIE INC. | $99 | Travel and Lodging | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-05-09 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-04-17 | Glaukos Corporation | $1,200 | Consulting Fee | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-04-09 | Glaukos Corporation | $21 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-04-08 | Alcon Vision LLC | $19 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2024 | |
| 2024-04-05 | ABBVIE INC. | $121 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2024 | |
| 2024-03-27 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2024 | |
| 2024-03-25 | Alcon Vision LLC | $14 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2024 | |
| 2024-03-06 | Glaukos Corporation | $2,400 | Consulting Fee | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-03-04 | Glaukos Corporation | $20 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-03-01 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2024 | |
| 2024-03-01 | Glaukos Corporation | $76 | Food and Beverage | Cash or cash equivalent | Radius Device, Glaucoma | 2024 | |
| 2024-02-28 | Glaukos Corporation | $59 | Food and Beverage | Cash or cash equivalent | iDose Device, Glaucoma | 2024 | |
| 2024-02-16 | Glaukos Corporation | $91 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-02-12 | Rayner Intraocular Lenses Limited | $18 | Food and Beverage | Cash or cash equivalent | Omidria Drug, Ophthalmology | 2024 | |
| 2024-02-08 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2024 | |
| 2024-02-02 | Johnson & Johnson Surgical Vision, Inc. | $130 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-22 | Sight Sciences, Inc. | $11 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2024 | |
| 2024-01-10 | Glaukos Corporation | $24 | Food and Beverage | Cash or cash equivalent | iStent Trabecular Micro-Bypass System Model iS3 Device, Glaucoma | 2024 | |
| 2024-01-09 | Alcon Vision LLC | $17 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2024 | |
| 2023-12-15 | Glaukos Corporation | $10 | Food and Beverage | Cash or cash equivalent | iStent infinite Trabecular Micro-Bypass System Model iS3 Device, Glaucoma | 2023 | |
| 2023-12-15 | Glaukos Corporation | $10 | Food and Beverage | Cash or cash equivalent | iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3 Device, Glaucoma | 2023 | |
| 2023-12-07 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | ALPHAGAN P Drug, EYE CARE | 2023 | |
| 2023-12-06 | ABBVIE INC. | $2,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2023 | |
| 2023-12-06 | Glaukos Corporation | $23 | Food and Beverage | Cash or cash equivalent | iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3 Device, Glaucoma | 2023 | |
| 2023-12-06 | Glaukos Corporation | $23 | Food and Beverage | Cash or cash equivalent | iStent infinite Trabecular Micro-Bypass System Model iS3 Device, Glaucoma | 2023 | |
| 2023-11-08 | Glaukos Corporation | $800 | Consulting Fee | Cash or cash equivalent | iStent Trabecular Micro-Bypass Stent System Device, Glaucoma | 2023 | |
| 2023-10-19 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-10-12 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2023 | |
| 2023-10-05 | ABBVIE INC. | $4,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-10-05 | Rayner Intraocular Lenses Limited | $19 | Food and Beverage | Cash or cash equivalent | Omidria Drug, Ophthalmology | 2023 | |
| 2023-10-02 | Alcon Vision LLC | $6 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-09-28 | NEW WORLD MEDICAL,INC. | $22 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-20 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-09-20 | ABBVIE INC. | $117 | Travel and Lodging | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-09-20 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-09-19 | Alcon Vision LLC | $16 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-09-18 | Glaukos Corporation | $15 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-09-18 | Alcon Vision LLC | $6 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-09-07 | ABBVIE INC. | $4,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-09-05 | Bausch & Lomb Americas Inc. | $19 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2023 | |
| 2023-08-31 | ABBVIE INC. | $866 | Travel and Lodging | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-08-31 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-08-31 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-08-11 | ABBVIE INC. | $2,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2023 | |
| 2023-08-03 | Apellis Pharmaceuticals, Inc. | $106 | Food and Beverage | Cash or cash equivalent | Syfovre Drug, Ophthalmology | 2023 | |
| 2023-08-02 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | ALPHAGAN P Drug, EYE CARE | 2023 | |
| 2023-08-01 | Glaukos Corporation | $13 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-07-13 | ABBVIE INC. | $2,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2023 | |
| 2023-06-13 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | ALPHAGAN P Drug, EYE CARE | 2023 | |
| 2023-06-12 | Glaukos Corporation | $18 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-06-05 | Alcon Vision LLC | $16 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-05-22 | Alcon Vision LLC | $6 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-05-09 | Glaukos Corporation | $27 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-05-09 | Sight Sciences, Inc. | $13 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2023 | |
| 2023-04-28 | Alcon Vision LLC | $20 | Food and Beverage | In-kind items and services | Rocklatan Drug, Ophthalmology | 2023 | |
| 2023-04-27 | Alcon Vision LLC | $115 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-04-24 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | ALPHAGAN P Drug, EYE CARE | 2023 | |
| 2023-04-20 | ABBVIE INC. | $3,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-04-11 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2023 | |
| 2023-04-11 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, EYE CARE | 2023 | |
| 2023-04-10 | Sight Sciences, Inc. | $14 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2023 | |
| 2023-04-06 | Alcon Vision LLC | $1,140 | Consulting Fee | Cash or cash equivalent | Simbrinza Drug, Ophthalmology | 2023 | |
| 2023-03-30 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-03-30 | ABBVIE INC. | $26 | Travel and Lodging | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-03-30 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2023 | |
| 2023-03-27 | LENSAR, Inc. | $16 | Food and Beverage | Cash or cash equivalent | LENSAR LASER SYSTEM Device, OPHTHALMOLOGY | 2023 | |
| 2023-03-24 | Glaukos Corporation | $15 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-03-20 | Alcon Vision LLC | $14 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-03-08 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | ALPHAGAN P Drug, EYE CARE | 2023 | |
| 2023-03-08 | Alcon Vision LLC | $14 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-03-05 | Johnson & Johnson Surgical Vision, Inc. | $154 | Food and Beverage | In-kind items and services | Tecnis IOL Device, Optics | 2023 | |
| 2023-03-03 | Glaukos Corporation | $33 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-03-02 | ABBVIE INC. | $104 | Food and Beverage | In-kind items and services | DURYSTA Drug, EYE CARE | 2023 | |
| 2023-02-20 | Glaukos Corporation | $23 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-02-20 | Alcon Vision LLC | $21 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-02-13 | Sight Sciences, Inc. | $13 | Food and Beverage | In-kind items and services | OMNI SURGICAL SYSTEM Device, Ophthalmology | 2023 | |
| 2023-01-30 | Alcon Vision LLC | $13 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2023 | |
| 2023-01-26 | Glaukos Corporation | $120 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-01-20 | Glaukos Corporation | $15 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-01-13 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | DURYSTA Drug, EYE CARE | 2023 | |
| 2022-12-23 | Glaukos Corporation | $21 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2022-12-20 | Bausch & Lomb Americas Inc. | $20 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2022 | |
| 2022-12-08 | ABBVIE INC. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LUMIGAN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-11-14 | Alcon Vision LLC | $101 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2022 | |
| 2022-11-14 | Glaukos Corporation | $16 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2022-11-02 | ABBVIE INC. | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, GLAUCOMA | 2022 | |
| 2022-11-02 | ABBVIE INC. | $121 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, GLAUCOMA | 2022 | |
| 2022-11-02 | ABBVIE INC. | $81 | Travel and Lodging | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, GLAUCOMA | 2022 | |
| 2022-11-02 | ABBVIE INC. | $1 | Travel and Lodging | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, GLAUCOMA | 2022 | |
| 2022-11-02 | ABBVIE INC. | $1 | Travel and Lodging | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, GLAUCOMA | 2022 | |
| 2022-10-27 | RxSight Inc | $130 | Food and Beverage | In-kind items and services | LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD) Device, Ophthalmology | 2022 | |
| 2022-10-26 | RxSight Inc | $23 | Food and Beverage | In-kind items and services | LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD) Device, Ophthalmology | 2022 | |
| 2022-10-19 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | LUMIGAN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-10-10 | Glaukos Corporation | $22 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2022-09-19 | Glaukos Corporation | $23 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2022-09-12 | Alcon Vision LLC | $13,903 | Acquisitions | Cash or cash equivalent | HYDRUS Microstent Device, Ophthalmology | 2022 | |
| 2022-08-08 | Bausch & Lomb Americas Inc. | $375 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | VYZULTA Drug, Ophthalmology | 2022 | |
| 2022-08-08 | Alcon Vision LLC | $98 | Food and Beverage | In-kind items and services | AcrySof IQ PanOptix UV IOL Device, Ophthalmology | 2022 | |
| 2022-08-08 | Glaukos Corporation | $17 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2022-07-21 | Alcon Vision LLC | $15 | Food and Beverage | In-kind items and services | rocklatan Drug, Glaucoma | 2022 | |
| 2022-07-14 | Alcon Vision LLC | $22 | Food and Beverage | In-kind items and services | HYDRUS Microstent Device, Ophthalmology | 2022 | |
| 2022-06-23 | Johnson & Johnson Surgical Vision, Inc. | $68 | Food and Beverage | In-kind items and services | CATALYS SYSTEM Device, Optics | 2022 | |
| 2022-06-20 | Glaukos Corporation | $15 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2022-06-16 | ABBVIE INC. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XEN GLAUCOMA TREATMENT SYSTEM Device, GLAUCOMA | 2022 | |
| 2022-06-09 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | DURYSTA Drug, GLAUCOMA | 2022 | |
| 2022-05-25 | Glaukos Corporation | $15 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2022-05-23 | ABBVIE INC. | $79 | Food and Beverage | In-kind items and services | XEN GLAUCOMA TREATMENT SYSTEM Device, GLAUCOMA | 2022 | |
| 2022-05-12 | ABBVIE INC. | $4,550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LUMIGAN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-05-12 | ABBVIE INC. | $938 | Travel and Lodging | In-kind items and services | LUMIGAN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-05-12 | ABBVIE INC. | $20 | Food and Beverage | Cash or cash equivalent | LUMIGAN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-05-12 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | LUMIGAN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-05-05 | ABBVIE INC. | $112 | Food and Beverage | In-kind items and services | LUMIGAN Drug, OPHTHALMOLOGY | 2022 | |
| 2022-05-03 | Bausch & Lomb Americas Inc. | $30 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2022 | |
| 2022-04-29 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | DURYSTA Drug, GLAUCOMA | 2022 | |
| 2022-04-27 | Glaukos Corporation | $18 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2022-04-24 | Glaukos Corporation | $38 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2022-04-23 | ABBVIE INC. | $1,012 | Consulting Fee | Cash or cash equivalent | DURYSTA Drug, GLAUCOMA | 2022 | |
| 2022-04-22 | Alcon Vision LLC | $94 | Food and Beverage | In-kind items and services | rocklatan Drug, Glaucoma | 2022 | |
| 2022-04-20 | Rayner Intraocular Lenses Limited | $12 | Food and Beverage | Cash or cash equivalent | Omidria Drug, Ophthalmology | 2022 | |
| 2022-03-18 | Alcon Vision LLC | $19 | Food and Beverage | In-kind items and services | AcrySof IQ VIVITY Device, Ophthalmology | 2022 | |
| 2022-01-27 | Alcon Vision LLC | $147 | Food and Beverage | In-kind items and services | ILUX Device, Ophthalmology | 2022 | |
| 2022-01-21 | Allergan, Inc. | $17 | Food and Beverage | In-kind items and services | DURYSTA Drug, GLAUCOMA | 2022 | |
| 2022-01-20 | SUN PHARMACEUTICAL INDUSTRIES INC. | $19 | Food and Beverage | In-kind items and services | Cequa Drug, Ophthalmology | 2022 | |
| 2022-01-19 | Glaukos Corporation | $30 | Food and Beverage | Cash or cash equivalent | ISTENT INJECT W Device, GLAUCOMA | 2022 | |
| 2021-12-06 | Ivantis, Inc | $99 | Gift | In-kind items and services | Hydrus Microstent Device, Ophthalmic Surgery | 2021 | |
| 2021-11-19 | Allergan, Inc. | $14 | Food and Beverage | In-kind items and services | DURYSTA Drug, GLAUCOMA | 2021 | |
| 2021-11-17 | Omeros Corporation | $18 | Food and Beverage | Cash or cash equivalent | Omidria Drug, Ophthalmology | 2021 | |
| 2021-11-14 | Allergan, Inc. | $26 | Food and Beverage | In-kind items and services | DURYSTA Drug, GLAUCOMA | 2021 | |
| 2021-11-13 | Aerie Pharmaceuticals, Inc. | $126 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-11-12 | Glaukos Corporation | $112 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-11-09 | Glaukos Corporation | $19 | Food and Beverage | In-kind items and services | iStent inject W Device, Glaucoma | 2021 | |
| 2021-10-21 | Allergan, Inc. | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LUMIGAN Drug, OPHTHALMOLOGY | 2021 | |
| 2021-10-21 | Allergan, Inc. | $109 | Food and Beverage | In-kind items and services | LUMIGAN Drug, OPHTHALMOLOGY | 2021 |
The latest 200 records of 433.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-17 | Glaukos Corporation | CENTER FOR SIGHT PL | $1,415 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-12-10 | Glaukos Corporation | CENTER FOR SIGHT PL | $640 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-11-26 | Glaukos Corporation | Uh Cleveland Medical Center | $200 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-11-19 | Glaukos Corporation | CENTER FOR SIGHT PL | $300 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-11-19 | Glaukos Corporation | CENTER FOR SIGHT PL | $370 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-10-22 | Glaukos Corporation | Uh Cleveland Medical Center | $200 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-10-22 | Glaukos Corporation | Uh Cleveland Medical Center | $400 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-10-08 | Glaukos Corporation | CENTER FOR SIGHT PL | $1,575 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-09-17 | Glaukos Corporation | Uh Cleveland Medical Center | $200 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-09-10 | Glaukos Corporation | CENTER FOR SIGHT PL | $6,640 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-09-10 | Glaukos Corporation | CENTER FOR SIGHT PL | $300 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-09-10 | Glaukos Corporation | CENTER FOR SIGHT PL | $370 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-08-27 | Glaukos Corporation | Greenphire, Inc. | $394 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-08-13 | Glaukos Corporation | OCPC | $59 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-08-13 | Glaukos Corporation | OCPC | $14 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-08-06 | Glaukos Corporation | CENTER FOR SIGHT PL | $1,500 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-07-23 | Glaukos Corporation | Greenphire, Inc. | $394 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-07-16 | Glaukos Corporation | Uh Cleveland Medical Center | $400 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-07-02 | Glaukos Corporation | CENTER FOR SIGHT PL | $545 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-07-02 | Glaukos Corporation | CENTER FOR SIGHT PL | $150 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-06-18 | Glaukos Corporation | OCPC | $17 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-06-11 | Glaukos Corporation | OCPC | $15 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-06-04 | Glaukos Corporation | CENTER FOR SIGHT PL | $890 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-06-04 | Glaukos Corporation | Greenphire, Inc. | $517 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-06-04 | Glaukos Corporation | CENTER FOR SIGHT PL | $545 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-05-29 | Glaukos Corporation | Greenphire, Inc. | $197 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-05-29 | Glaukos Corporation | Greenphire, Inc. | $197 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-05-14 | Glaukos Corporation | Greenphire, Inc. | $394 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-05-14 | Glaukos Corporation | OCPC | $114 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-05-07 | Glaukos Corporation | CENTER FOR SIGHT PL | $1,160 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-04-29 | Glaukos Corporation | Uh Cleveland Medical Center | $475 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-04-02 | Glaukos Corporation | Greenphire, Inc. | $517 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-03-12 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-03-05 | Glaukos Corporation | CENTER FOR SIGHT PL | $1,260 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-03-05 | Glaukos Corporation | Amazon.com, Inc. | $4 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-02-26 | Glaukos Corporation | Greenphire, Inc. | $394 | A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WIT | 2025 |
| 2025-02-19 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-02-12 | Glaukos Corporation | CENTER FOR SIGHT PL | $5,885 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-02-12 | Glaukos Corporation | Precision Vision | $205 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-01-29 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-01-08 | Glaukos Corporation | CENTER FOR SIGHT PL | $6,375 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-01-08 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2025 |
| 2025-01-08 | Glaukos Corporation | CENTER FOR SIGHT PL | $500 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2025 |
| 2024-12-11 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-12-04 | Glaukos Corporation | CENTER FOR SIGHT PL | $1,230 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-12-04 | ABBVIE INC. | CENTER FOR SIGHT PL | $5,686 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2024-12-04 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-11-06 | Glaukos Corporation | CENTER FOR SIGHT PL | $545 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-11-06 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-11-06 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-10-30 | Glaukos Corporation | Clinigen Clinical Supplies Management | $22 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-10-09 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-10-03 | ABBVIE INC. | CENTER FOR SIGHT PL | $1,017 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2024-09-25 | Glaukos Corporation | Clinigen Clinical Supplies Management | $54 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-09-18 | Glaukos Corporation | Greenphire, Inc. | $517 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-08-02 | ABBVIE INC. | CENTER FOR SIGHT PL | $2,311 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2024-07-17 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-07-17 | Glaukos Corporation | Greenphire, Inc. | $258 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-07-05 | ABBVIE INC. | CENTER FOR SIGHT PL | $1,239 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2024-07-03 | Glaukos Corporation | CENTER FOR SIGHT PL | $520 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-06-19 | Glaukos Corporation | Greenphire, Inc. | $517 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-06-12 | Glaukos Corporation | Precision Vision | $203 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-06-05 | Glaukos Corporation | CENTER FOR SIGHT PL | $370 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-06-05 | ABBVIE INC. | CENTER FOR SIGHT | $675 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2024-06-05 | Glaukos Corporation | Uh Cleveland Medical Center | $90 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2024 |
| 2024-05-08 | ABBVIE INC. | CENTER FOR SIGHT | $1,017 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2024-05-08 | Glaukos Corporation | CENTER FOR SIGHT PL | $9,725 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-04-04 | ABBVIE INC. | CENTER FOR SIGHT | $1,239 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2024-04-03 | Glaukos Corporation | Commercial Print Management | $82 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-03-07 | ABBVIE INC. | CENTER FOR SIGHT | $675 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2024-03-06 | Glaukos Corporation | Commercial Print Management | $250 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-03-06 | Glaukos Corporation | CENTER FOR SIGHT PL | $845 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2024 |
| 2024-02-01 | ABBVIE INC. | CENTER FOR SIGHT | $3,153 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2024-01-04 | Glaukos Corporation | Greenphire, Inc. | $1,055 | Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular imp | 2024 |
| 2024-01-04 | ABBVIE INC. | CENTER FOR SIGHT | $10,827 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2024 |
| 2023-12-06 | Glaukos Corporation | CENTER FOR SIGHT PL | $415 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-11-29 | Glaukos Corporation | Clinigen Clinical Supplies Management | $83 | Multicenter Randomized Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular impla | 2023 |
| 2023-11-16 | Glaukos Corporation | Uh Cleveland Medical Center | $100 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-11-07 | ABBVIE INC. | CENTER FOR SIGHT PL | $1,239 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2023 |
| 2023-11-01 | Glaukos Corporation | CENTER FOR SIGHT PL | $895 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-10-25 | Glaukos Corporation | Clinigen Clinical Supplies Management | $83 | Multicenter Randomized Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular impla | 2023 |
| 2023-10-04 | Glaukos Corporation | Clinigen Clinical Supplies Management | $470 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-09-13 | Glaukos Corporation | CENTER FOR SIGHT PL | $560 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-09-05 | ABBVIE INC. | CENTER FOR SIGHT PL | $1,239 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2023 |
| 2023-08-31 | ABBVIE INC. | CENTER FOR SIGHT PL | $2,600 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2023 |
| 2023-08-16 | Glaukos Corporation | Clinigen Clinical Supplies Management | $191 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-08-15 | ABBVIE INC. | CENTER FOR SIGHT PL | $5,525 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2023 |
| 2023-08-09 | ABBVIE INC. | CENTER FOR SIGHT PL | $9,469 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2023 |
| 2023-08-02 | Glaukos Corporation | CENTER FOR SIGHT PL | $150 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-07-05 | Glaukos Corporation | CENTER FOR SIGHT PL | $415 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-07-03 | ABBVIE INC. | CENTER FOR SIGHT PL | $1,357 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2023 |
| 2023-06-28 | Glaukos Corporation | Clinigen Clinical Supplies Management | $594 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-06-02 | Alcon Research LLC | Center For Sight, Eva I. Liang MD, | $8,690 | A MULTICENTER, OPEN-LABEL ROCKLATAN EVALUATION OF IOP LOWERING EFFICACY AND SAFETY AS REPLACEMENT OF CURRENT MEDICAL THE | 2023 |
| 2023-06-01 | Glaukos Corporation | CENTER FOR SIGHT PL | $565 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-05-24 | Glaukos Corporation | Uh Cleveland Medical Center | $270 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-04-28 | Glaukos Corporation | CENTER FOR SIGHT PL | $560 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-04-19 | Glaukos Corporation | Uh Cleveland Medical Center | $90 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-03-29 | Glaukos Corporation | Clinigen Clinical Supplies Management | $345 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-03-29 | Glaukos Corporation | CENTER FOR SIGHT PL | $895 | Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophtha | 2023 |
| 2023-03-09 | ABBVIE INC. | CENTER FOR SIGHT PL | $6,000 | Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Impl | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Venice, FL, county Sarasota County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Venice, FL | County Sarasota County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 27,479 | 459,547 | 22,416,077 |
| Population, 2020 census P1 | 25,463 | 434,006 | 21,538,187 |
| Median age B01002 | 69.2 | 57.4 | 42.6 |
| Under 18 B01001 | 5.3% | 14.0% | 19.5% |
| 65 and over B01001 | 61.4% | 37.5% | 21.3% |
| Households B11001 | 15,027 | 212,204 | 8,752,810 |
| Foreign born B05002 | 11.7% | 13.0% | 21.9% |
| Median household income B19013 | $76,755 | $83,416 | $74,568 |
| Median family income B19113 | $104,962 | $102,230 | $89,891 |
| Per capita income B19301 | $75,070 | $57,835 | $42,609 |
| Poverty rate B17001 | 9.2% | 8.6% | 12.6% |
| Unemployment rate B23025 | 4.8% | 3.7% | 4.8% |
| Civilian labor force B23025 | 8,036 | 197,073 | 11,016,578 |
| Mean commute (minutes) B08013 | 26.1 | 24.5 | 28.0 |
| Bachelor's degree or higher B15003 | 46.3% | 40.8% | 34.1% |
| Housing units B25001 | 20,966 | 266,492 | 10,256,470 |
| Owner-occupied B25003 | 80.4% | 76.7% | 67.6% |
| Renters B25003 | 19.6% | 23.3% | 32.4% |
| Median home value B25077 | $434,700 | $411,800 | $359,000 |
| Median gross rent B25064 | $1,606 | $1,818 | $1,669 |
| White, not Hispanic B03002 | 87.4% | 80.0% | 50.4% |
| Black B03002 | 1.2% | 3.9% | 14.6% |
| Hispanic or Latino B03002 | 6.0% | 10.7% | 27.4% |
| Asian B03002 | 2.1% | 1.9% | 2.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Venice, FL.
Comments